Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APEX trial of extended-duration betrixaban versus enoxaparin for venous thromboembolism prevention in acutely ill medical patients
2012-000255-13Phase 3Completed
- Sponsor
- Portola Pharmaceuticals
- Start
- Apr 2012
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in venous thromboembolism (VTE) comparing Extended-duration betrixaban with Standard-of-care enoxaparin (2 arms). Primary endpoint: Prevention of venous thromboembolism. Started Apr 2012; status: completed.
02
Drugs
betrixabanenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2012-000255-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000255-13.